SEC Filings

Form 425
SEELOS THERAPEUTICS, INC. filed this Form 425 on 01/04/2019
Document Outline
Entire Document (377.9 KB)
Subdocument 1 - 425 - 8-K
Page 1 - UNITED STATES
Page 2 - Item 1.01Entry into a Material Definitive Agreement
Page 3 - Transaction Document
Page 4 - Proposal No. 2:
Page 5 - Item 9.01Financial Statements and Exhibits.
Page 6 - Important Additional Information and Where to Find It
Page 7 - SIGNATURES
Subdocument 2 - EX-10.1 - EXHIBIT 10.1
Page 1 - Exhibit 10.1
Page 2 - A-1 WarrantA-2 Warrant
Page 3 - [INSERT IN SERIES A WARRANT:the greater of 100% and average of the Weighted Average Priceshighest We
Page 4 - [INSERT IN SERIES A WARRANT:Black Scholes Valuethe greater of 100% andaverage of the Weighted Averag
Page 5 - 8-K Filing
Page 6 - N/A
Page 7 - IN WITNESS WHEREOF,
Page 8 - IN WITNESS WHEREOF,
Page 9 - IN WITNESS WHEREOF,
Subdocument 3 - EX-99.1 - EXHIBIT 99.1
Page 1 - UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Page 2 - N/A
Page 3 - Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2018
Page 4 - Unaudited Pro Forma Condensed Combined Statement of Operations Nine Months Ended
Page 5 - Notes to the Unaudited Pro Forma Condensed Combined Financial Information
Page 6 - Basis of Presentation
Page 7 - Payments Toward the Acquisition of Asset from Vyera Pharmaceuticals, AG ( Vyera )
Page 8 - Note 4 - Pro forma adjustments